RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q2 2023
Top Holdings54 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 11.2M | $1B | 18.9% | $92.74 | -5.65% | 19 qtrssince 2018-Q4 | Increased 89 |
Legend Biotech Corp. Sponsored ADR | 6.3M | $432.5M | 8.2% | $58.65 | +19.69% | 4 qtrssince 2022-Q3 | Increased 98 |
VAXCYTE INC | 7.9M | $394.1M | 7.4% | $35.32 | +37.34% | 13 qtrssince 2020-Q2 | Increased 66 |
DICE THERAPEUTICS INC | 7.9M | $365M | 6.9% | — | — | 8 qtrssince 2021-Q3 | Unchanged 0 |
89BIO INC | 11.4M | $216.4M | 4.1% | — | — | 15 qtrssince 2019-Q4 | Unchanged 0 |
BIOGEN IDEC INC | 532,892 | $151.8M | 2.9% | $222.99 | +26.52% | 6 qtrssince 2022-Q1 | Unchanged 0 |
| 8.3M | $141.7M | 2.7% | — | — | 9 qtrssince 2021-Q2 | Unchanged 0 | |
VERONA PHARMA PLC | 6.3M | $133.6M | 2.5% | — | — | 12 qtrssince 2020-Q3 | Unchanged 0 |
CUREVAC N V | 12.2M | $127.6M | 2.4% | $6.67 | +63.12% | 2 qtrssince 2023-Q1 | Unchanged 0 |
TYRA BIOSCIENCES INC | 7.2M | $123.2M | 2.3% | $16.91 | -2.25% | 8 qtrssince 2021-Q3 | Unchanged 0 |
NewAmsterdam Pharma Company N.V. | 9M | $107M | 2.0% | $11.58 | +4.68% | 3 qtrssince 2022-Q4 | Increased 83 |
CYTEK BIOSCIENCES INC | 12.3M | $105M | 2.0% | $18.15 | -54.76% | 8 qtrssince 2021-Q3 | Decreased 0 |
JANUX THERAPEUTICS INC | 8.7M | $102.9M | 1.9% | $25.37 | -54.55% | 9 qtrssince 2021-Q2 | Unchanged 0 |
GERON CORP | 31.5M | $101.3M | 1.9% | $2.12 | +45.04% | 13 qtrssince 2020-Q2 | Unchanged 0 |
Inhibrx Biosciences, Inc. | 3.9M | $100M | 1.9% | — | — | 3 qtrssince 2022-Q4 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 5.7M | $93.6M | 1.8% | $23.28 | -28.23% | 19 qtrssince 2018-Q4 | Increased 48 |
DAY ONE BIOPHARMACEUTICALS I | 7.8M | $93.2M | 1.8% | $18.91 | -35.12% | 9 qtrssince 2021-Q2 | Increased 52 |
RXSIGHT INC | 3.1M | $87.9M | 1.7% | $12.40 | +133.06% | 8 qtrssince 2021-Q3 | Unchanged 0 |
Cogent Biosciences, Inc. | 6.4M | $76M | 1.4% | $13.34 | -13.25% | 4 qtrssince 2022-Q3 | Increased 50 |
PEPGEN INC | 8.1M | $72.7M | 1.4% | $10.40 | -6.15% | 5 qtrssince 2022-Q2 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $5.3B across 54 positions as of Q2 2023. Top holdings: ASND (18.9%), LEGN (8.2%), PCVX (7.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 4 new positions, 9 exits, 10 increased. Top move: LEGN (INCREASED, conviction 98). Portfolio: $5.3B across 54 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer